SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Albany Molecula...
November 19 2014 - 9:40PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Eastern
District of New York on behalf of purchasers of Albany Molecular
Research, Inc. (“Albany Molecular” or the “Company”) (Nasdaq: AMRI)
common stock during the period between August 5, 2014 and November
5, 2014, inclusive (the “Class Period”). Investors who wish to
become proactively involved in the litigation have until January
12, 2015 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Albany Molecular
common stock purchased on or after August 5, 2014 and held through
the revelation of negative information during and/or at the end of
the Class Period, as described below, and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. No class has yet been certified in the above action.
Members of the Class will be represented by the lead plaintiff and
counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement and how much of a settlement to accept for the Class in
the action. The lead plaintiff will be selected from among
applicants claiming the largest loss from investment in Company
units during the Class Period. Brower Piven also encourages anyone
with information regarding the Company’s conduct during the period
in question to contact the firm, including whistleblowers, former
employees, shareholders and others.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that when the Company
announced an increase in its 2014 adjusted EPS guidance to reflect
the addition of OsoBio and the strengthening of its contract
business on August 5, 2014, there had been since July an
undisclosed business interruption event at the OsoBio facility that
would not be back online until some undisclosed time in the future.
According to the complaint, following the Company’s November 5,
2014 announcement of the existence and continuation of the July
business interruption event at its OsoBio facility, the value of
Albany Molecular shares declined significantly.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Sep 2023 to Sep 2024